entertainment -WSS

entertainment

author：focus 2025-08-23 06:54:30 - browse：485

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Life science postdocs should get big pay hike, NIH panel says

WSS

7 people shot in DC, police say

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Hospital chaplains balance Covid safety with patients’ spiritual needs

7 people shot in DC, police say

A new study asks: Are we harming blood donors by taking blood?

Australia's humpback populations rebound raising hopes of marine scientists

entertainment

entertainment

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

As demand for Covid shots wanes, Moderna seeks its next success

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Peter Hotez and the public health issue of online harassment

Does Paxlovid work in people vaccinated against Covid

Drug repurposing or repositioning? The language matters

Grail is spending more than ever lobbying Congress

DIEP, the 'gold standard' of breast reconstruction, is under threat

Merck to acquire Harpoon Therapeutics for $680 million

focus

Why is France rioting? What to know about the fatal police shooting of Nahel M

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Stories you might have missed in 2023: health, science, medicine

At JPM 2024, hospital systems pitch financial strength to investors

Community addresses injustice for Long Island mothers

Why is France rioting? What to know about the fatal police shooting of Nahel M

explore

leisure time

explore

hotspot